Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings
Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-27 | English | |
| 10-Q | 2026-05-15 | English | |
| 8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer) | 2026-05-07 | English | |
| 8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer) | 2026-05-01 | English | |
| ARS - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer) | 2026-04-20 | English | |
| DEF 14A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer) | 2026-04-20 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 47571870 | 8-K | 2026-05-27 | English | ||
| 46362416 | 10-Q | 2026-05-15 | English | ||
| 43589591 | 8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer) | 2026-05-07 | English | ||
| 39511231 | 8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer) | 2026-05-01 | English | ||
| 34694048 | ARS - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer) | 2026-04-20 | English | ||
| 34694060 | DEF 14A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer) | 2026-04-20 | English | ||
| 31605551 | 8-K Filing | 2026-02-17 | English | ||
| 31605641 | S-1 Filing | 2026-02-11 | English | ||
| 31605635 | S-1/A Filing | 2026-02-11 | English | ||
| 31605562 | 8-K Filing | 2026-02-02 | English | ||
| 31605550 | 424B3 Filing | 2026-02-02 | English | ||
| 13144026 | 8-K | 2026-01-12 | English | ||
| 13144027 | 3 | 2026-01-12 | English | ||
|
2025
2 filings
| |||||
| 13144028 | 8-K | 2025-12-29 | English | ||
| 13144029 | S-1/A | 2025-12-11 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Shuttle Pharmaceuticals Holdings, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35448/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35448 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35448 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35448 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35448}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Shuttle Pharmaceuticals Holdings, Inc. (id: 35448)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.